<https://rdf.molmedb.upol.cz/reference/ref4247> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM494902>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.2c00534"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/bibliographicCitation> "Abram M, Jakubiec M, Reeb K, Cheng MH, Gedschold R, Rapacz A, Mogilski S, Socała K, Nieoczym D, Szafarz M, Latacz G, Szulczyk B, Kalinowska-Tłuścik J, Gawel K, Esguerra CV, Wyska E, Müller CE, Bahar I, Fontana ACK, Wlaź P, Kamiński RM, Kamiński K.: Discovery of (<i>R</i>)-<i>N</i>-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [<b>(<i>R</i>)-AS-1</b>], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity <i>In Vivo</i>. J Med Chem, Volume 65 (17), 2022"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/ontology/bibo/pmid> "35984707"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method30>,
		<https://rdf.molmedb.upol.cz/interaction/membrane18> .
<https://rdf.molmedb.upol.cz/interaction/int1021116> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4247> .
